|
KMID : 1137020210320060095
|
|
Journal of Gynecologic Oncology
2021 Volume.32 No. 6 p.95 ~ p.95
|
|
|
Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020
|
|
Obermair Andreas
Beale Philip
Scott Clare L.
Beshay Victoria
Kichenadasse Ganessan
Simcock Bryony
Nicklin James
Lee Yeh Chen
Cohen Paul
Meniawy Tarek
|
|
|
Abstract
|
|
|
|
Epithelial ovarian cancer (EOC) is among the top ten causes of cancer deaths worldwide, and is one of the most lethal gynecological malignancies in high income countries, with incidence and death rates expected to rise particularly in Asian countries where ovarian cancer is among the 5 most common cancers. Despite the plethora of randomised clinical trials investigating various systemic treatment options in EOC over the last few decades, both progression-free and overall survival have remained at approximately 16 and 40 months respectively. To date the greatest impact on treatment has been made by the use of poly (ADP-ribose) polymerase (PARP) inhibitors in women with advanced EOC and a BRCA1/2 mutation. Inhibition of PARP, the key enzyme in base excision repair, is based on synthetic lethality whereby alternative DNA repair pathways in tumor cells that are deficient in homologous recombination is blocked, rendering them unviable and leading to cell death. The Australia New Zealand Gynaecological Oncology Group (ANZGOG) is the national gynecological cancer clinical trials organization for Australia and New Zealand. ANZGOG's purpose is to improve outcomes and quality of life for women with gynecological cancer through cooperative clinical trials and undertaking multidisciplinary research into the causes, prevention and treatments of gynecological cancer. This review summarizes current ovarian cancer research and treatment approaches presented by Australian and New Zealand experts in the field at the 2020 ANZGOG webinar series entitled “Ovarian Cancer systems of Care”.
|
|
|
KEYWORD
|
|
|
Ovarian Cancer, PARP Inhibitors, High-Grade Serous Ovarian Cancer, Neoadjuvant Chemotherapy, Homologous Recombination Deficiency, BRCA1/2 Mutation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|